Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.61 |
| ▸ | CES1 | P23141 | 2/20 | 0.61 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | GRM8 | O00222 | 1/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.41 |
| ▸ | ACP3 | P15309 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10443875 | 0.81 | HDAC3 (0.41) | CES2CES1LMNAHTT | |
| SCHEMBL13170119 | 0.81 | CES2 (0.65) | CES2CES1EPHX2GSK3BACP3 | |
| SCHEMBL504285 | 0.79 | CES2 (0.67) | CES2CES1EPHX2GSK3BLMNA | |
| SCHEMBL4634324 | 0.79 | CES2 (0.67) | CES2CES1EPHX2GSK3BLMNA | |
| SCHEMBL504284 | 0.79 | CES2 (0.67) | CES2CES1EPHX2GSK3BLMNA | |
| SCHEMBL13687637 | 0.78 | CES2 (0.61) | CES2CES1EPHX2GSK3BACP3 | |
| SCHEMBL9280967 | 0.77 | BRD4 (0.46) | LMNA | |
| SCHEMBL7470401 | 0.77 | CES2 (0.65) | CES2CES1EPHX2GSK3BGRM8 | |
| SCHEMBL841509 | 0.77 | CES2 (0.65) | CES2CES1EPHX2GSK3BGRM8 | |
| SCHEMBL6676161 | 0.76 | CES2 (0.59) | CES2CES1EPHX2AKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093427-B2 | Construction and screening of solution-phase derived library of fenbufen and ethacrynic acid | NATIONAL TSING HUA UNIVERSITY (TW) | 2012-01-10 | — | — | US | disclosed |
| US-8093427-B2 | Construction and screening of solution-phase derived library of fenbufen and ethacrynic acid | NATIONAL TSING HUA UNIVERSITY (TW) | 2012-01-10 | — | — | US | disclosed |
| US-20110306668-A1 | CONSTRUCTION AND SCREENING OF SOLUTION-PHASE DERIVED LIBRARY OF FENBUFEN AND ETHACRYNIC ACID | NATIONAL TSING HUA UNIVERSITY (TW) | 2011-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306668-A1 | CONSTRUCTION AND SCREENING OF SOLUTION-PHASE DERIVED LIBRARY OF FENBUFEN AND ETHACRYNIC ACID | CYP4F2, ACR, CYP4F3 | CES2 13/4885CES1 180/4885EPHX2 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.